Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hepatology ; 14(1): 91-8, 1991 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-2066075

RESUMO

Aztreonam and cefotaxime were compared in 44 cirrhotic patients who had 52 episodes of gram-negative spontaneous peritonitis. Patients were randomized into two therapeutic groups of similar characteristics. Group A (28 episodes) received 0.5 gm of aztreonam every 8 hr, and group B (24 episodes) received 1 gm of cefotaxime every 6 hr, for a planned 14-day period. Peak and trough serum and ascitic fluid levels of both antibiotics were several times higher than the minimum inhibitory concentrations of causative microorganisms. Eleven patients (21%) died within the first 48 hr after beginning therapy, which included seven in the aztreonam group and four in the cefotaxime group. In the remaining patients, signs and symptoms of infection were promptly controlled, and ascitic fluid cultures became negative after 48 hr in all cases, except in one patient from the aztreonam group, who was a clinical failure. Two patients from the aztreonam group and one from the cefotaxime group relapsed after treatment. The overall mortality rate was 50%, which was lower than classically reported: 12 patients (43%) died in the aztreonam group, and 14 (58%) died in the cefotaxime group (p = 0.265, NS). Hepatorenal syndrome and digestive tract hemorrhage were the most frequent causes of death occurring after the first 48 hr of treatment. Streptococcal superinfections developed in three patients (14.2%) in the aztreonam group. We conclude that both antibiotics at the low doses used in this study are similarly well tolerated and effective in controlling this infection. Because the use of aztreonam as the initial empirical treatment requires a concomitant antibiotic against gram-positive infections and the possibility of streptococcal superinfections, cefotaxime seems to be a more advantageous therapeutic alternative for this patient population.


Assuntos
Aztreonam/uso terapêutico , Infecções Bacterianas , Cefotaxima/uso terapêutico , Bactérias Gram-Negativas , Cirrose Hepática/complicações , Peritonite/microbiologia , Adulto , Idoso , Líquido Ascítico/complicações , Líquido Ascítico/metabolismo , Aztreonam/sangue , Cefotaxima/sangue , Feminino , Humanos , Rim/fisiopatologia , Masculino , Pessoa de Meia-Idade , Peritonite/complicações , Peritonite/fisiopatologia , Estudos Prospectivos , Superinfecção/microbiologia
2.
Arch Esp Urol ; 43(3): 237-9, 1990 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-2369155

RESUMO

Attention is focussed on urachal cysts, an uncommon disease entity recognized in 1 out of 5,000 autopsies performed in children. Two male patients, aged 47 and 30 years are described herein. Ultrasonography is considered to be necessary for diagnosing this disease. Treatment by complete removal of the cyst is advocated while others suggest the possibility of a more aggressive approach: removal combined with resection of a bladder anuria to avoid recurrence or development of a carcinoma.


Assuntos
Cisto do Úraco/cirurgia , Adulto , Humanos , Masculino , Pessoa de Meia-Idade , Supuração
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...